Highlights Medigene AG

Equities

MDG1

DE000A1X3W00

Real-time Estimate Tradegate Other stock markets 08:35:17 2024-05-21 am EDT			5-day change	1st Jan Change
1.32 ^EUR	-5.04%		-12.08%	-14.10%

12:46pm	Medigene, BioNTech Extend Cancer Immunotherapy Partnership	MT
May. 15	Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medigene, BioNTech Extend Cancer Immunotherapy Partnership	06:46am	MT
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	May. 15	CI
Medigene Ag Maintains Earnings Guidance for 2024	May. 14	CI
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	May. 02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	May. 02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	Apr. 25	CI
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	Apr. 23	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	Apr. 08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	Apr. 04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	Apr. 04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Medigene Ag Provides Earnings Guidance for 2024	Mar. 28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	Mar. 04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	Feb. 12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	Nov. 21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	Nov. 04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	23-10-16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23-08-23	CI
Medigene AG Provides Revenue Guidance for 2023	23-08-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Medigene AG

Equities

MDG1

DE000A1X3W00

Highlights

Filters